Bio-Path Holdings(BPTH)

Focus: Bio-Path Holdings is a public biotechnology company focused on antisense DNA therapeutics for hematologic malignancies and solid tumors. The company operates at pre-revenue stage with a highly focused pipeline of early-stage gene therapy programs.

Gene Therapy

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Bio-Path Holdings

AI assessmentNot Hiring

No open roles listed right now. Follow Bio-Path Holdings to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BP1001-A

Solid Tumor, Adult

PHASE_1

L-Bcl-2 antisense oligonucleotide

Mantle Cell Lymphoma

PHASE_1

BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide

Help build intelligence for Bio-Path Holdings

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused antisense DNA platform with potential to define a new therapeutic modality in oncology if BP1001 demonstrates efficacy in Phase 1/2 CML trials
Public company status provides liquidity and potential equity upside, unlike private biotech peers
Lean R&D operation ($12M annual spend) offers potential for high scientific impact per capita in a specialized niche

Watch Out For

Severe cash crisis: cash position collapsed from $10M (FY2023) to $1M (FY2024) while burn accelerated to $16M net loss—existential runway concern
Zero active job openings and no hiring activity suggests frozen headcount or potential insolvency trajectory
All 6 programs remain in Phase 1/2 with no Phase 3 candidates, no approved products, and no commercial revenue—execution risk is extreme

Generated by Claude from Bio-Path Holdings's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.